Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Gland Pharma Ltd Performance

Today's Low
1,735.00
arrowIcon
Today's High
1,781.35
52 Wk Low
861.00
arrowIcon
52 Wk High
2,194.00


Open

1776.2

Traded Value (Cr)

147.04 Cr

Prev. Close

1792.4

VWAP

1751.13

Volume

5,21,014

Face Value

1

Gland Pharma Ltd Fundamentals

Market Cap
₹ 29,535 Cr
P/E Ratio (TTM)
42.59
P/B Ratio
3.56
Debt to Equity
0.04
ROE
8.41 %
EPS (TTM)
42.10
Dividend Yield
0.00%
Book Value
504.32

Click here to know more about Fundamentals

Gland Pharma Ltd Financials

Gland Pharma Ltd Financials

Gland Pharma Ltd Shareholding Pattern

Held By Dec 2023 Sep 2023 Jun 2023 Mar 2023
Promoters 57.86 % 57.86 % 57.86 % 57.86 %
Mutual Funds 21.34 % 19.79 % 20.48 % 20.25 %
Others 12.98 % 12.92 % 13.26 % 13.30 %
FII 4.04 % 4.91 % 2.80 % 4.33 %
Retail 3.79 % 4.52 % 5.60 % 4.26 %

Promoters

57.86%

Mutual Funds

21.34%

Others

12.98%

FII

4.04%

Retail

3.79%

Promoters

57.86%

Mutual Funds

19.79%

Others

12.92%

FII

4.91%

Retail

4.52%

Promoters

57.86%

Mutual Funds

20.48%

Others

13.26%

FII

2.80%

Retail

5.60%

Promoters

57.86%

Mutual Funds

20.25%

Others

13.30%

FII

4.33%

Retail

4.26%

Resistance and Support

₹1,792.03

PIVOT

resistance-arrow
Resistance
First Resistance₹1,813.067
Second Resistance₹1,833.733
Third Resistance₹1,854.767
support-arrow
Support
First Resistance₹1,771.367
Second Resistance₹1,750.333
Third Resistance₹1,729.667
RSI55.362
MACD15.877
ADX14.687
CCI-57.488

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day521,014456,88954.36
Week3,955,7232,397,81253.19
1 Month899,602537,38051.24
6 Months521,014314,05860.28

About Gland Pharma Ltd

Gland Pharma Ltd was incorporated as Gland Pharma Private Limited', a private limited company under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the Company was changed to Gland Pharma Limited' pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994 and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956. The Company is primarily engaged in manufacturing injectable formulations. The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The company has 8 manufacturing facilities in India, comprising four finished formulations facilities with a total of 23 production lines and three API facilities. The company sells products primarily under a business to business (B2B) model in over 60 countries as of March 31, 2022, including the United States, Europe, Canada, Australia, India and the Rest of the world. The company has a consistent compliance track record with a range of regulatory regimes across these markets. The company also have an extensive track record in complex injectables development, manufacturing and marketing and a close understanding of the related sophisticated scientific, technical and regulatory processes. The company has expanded it nature of business from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems. Over the years, the company has made substantial investments in the companies manufacturing infrastructure to support the product portfolio needs and reach. The company has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. The companies API facilities provide with in-house manufacturing capabilities for critical APIs, enabling the company to control costs and quality and mitigate supply chain related risks around the key products. The companies capabilities as a vertically integrated company include internal research and development (R&D) expertise, robust manufacturing capabilities, a strict quality assurance system, extensive regulatory experience and established marketing and distribution relationships. As of March 31, 2020, the company along with partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products. Out of these 265 ANDA filings, 100 represent ANDAs owned by the company, of which 63 ANDA filings are approved and 37 are pending approval. As of the same date, the company along with partners had a total of 1,415 product registrations, comprising 368 product registrations in the United States, Europe, Canada and Australia, 54 in India and 993 in the Rest of the world. The company also has a consistent regulatory compliance track record and all the facilities are approved by the USFDA from whom the company have had no warning letters since the inception of each facility. Other key regulatory agencies for which certain of our facilities have approvals include MHRA (UK), TGA (Australia), ANVISA (Brazil), AGES (Austria) and BGV Hamburg (Germany). During the year 2020-21, the Company has incorporated Gland Pharma International Pte. Ltd., a Wholly-owned Subsidiary in Singapore. It has incurred capital expenditure of Rs. 2,287.76 million at its manufacturing facilities at Dundigal, Pashamylaram, VSEZ and Pharmacity. It has issued and allotted 8,333,333 fully paid-up equity shares in the Initial Public Offer during November, 2020. During FY 2022, the Company launched 47 product SKUs of 28 molecules like Micafungin, Ziprasidone, Bivalirudin RTU and Olapatadine Ophthalmic (OTC). As of March 31, 2022, it along with the partners had 284 ANDA filings in the US, of which 234 were approved and 50 were pending approval. Out of these, 115 were owned by the Company with 85 approvals and 30 pending for approval. It had manufacturing capacity for finished formulations of approximately 767 million units per annum. It filed 21 ANDAs, 5 DMFs and received 32 ANDA approvals. It signed an agreement to supply upto 252 million doses of RDIF's Sputnik V COVID-19 vaccine. It purchased assets of Vitane Biologics, Hyderabad based biopharmaceutical company. On 27th April, 2023, Gland Pharma International Pte. Ltd., Wholly Owned Subsidiary of the Company acquired Phixen SAS and 3 holding companies in Cenexi for a purchase consideration costing Euro 114,259,004.44 and repaid a loan of Euro 79,457,194.11 on behalf of the Sellers through Share Purchase Agreement dated 6th January, 2023 and as a result, Phixen SAS and the Cenexi Holding Entities became the Wholly Owned step-down Subsidiaries of the Company, which in turn resulted in indirect acquisition of 7 subsidiaries of Cenexi, a) Cenexi SAS, (b) Cenexi Services SAS, (c) Cenexi HSC SAS, (d) Cenexi 2 SASU, (e) Cenexi 3 SASU, (f) Cenexi Laboratories Thissen SA and (g) Phineximmo SA. 'Dexrazoxane' the first product was launched in China during the year 2023.

Managing Director

SRINIVAS SADU

Founded

1978

NSE Symbol

GLAND

Gland Pharma Ltd Management

NameDesignation
Yiu Kwan Stanley LauChairman & Independent Directo
SRINIVAS SADUManaging Director & CEO
QIYU CHENNon-Exec & Non-Independent Dir
UDO JAHANNES VETTERNon-Exec & Non-Independent Dir
C S N MurthyIndependent Director
ESSAJI GOOLAM VAHANVATIIndependent Director
Naina Lal KidwaiIndependent Director
Jia Ai (Allen) ZhangNon-Exec & Non-Independent Dir
Yao FangNon-Exec & Non-Independent Dir

Gland Pharma Ltd News

Volumes soar at Gland Pharma Ltd counter
Gland Pharma Ltd recorded volume of 136.71 lakh shares by 14:14 IST on NSE, a 68.49 times surge over two-week average daily volume of 2.00 lakh shares
Gland Pharma rallies on USFDA nod for breast cancer drug
Gland Pharma advanced 5.88% to Rs 1,858.40 after it received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection.
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
Gland Pharma allots 2,400 equity shares under ESOS
Gland Pharma Ltd slips for fifth straight session
Gland Pharma Ltd is quoting at Rs 1871.65, down 1.42% on the day as on 13:19 IST on the NSE. The stock jumped 42.97% in last one year as compared to a 27.42% rally in NIFTY and a 59.26% spurt in the Nifty Pharma index.
Gland Pharma consolidated net profit declines 17.28% in the December 2023 quarter
Sales rise 64.68% to Rs 1545.16 crore
Gland Pharma allots 6,200 equity shares under ESOS
Gland Pharma Ltd gains for fifth session
Gland Pharma Ltd is quoting at Rs 2024, up 1.27% on the day as on 12:44 IST on the NSE. The stock is up 72.59% in last one year as compared to a 23.41% gain in NIFTY and a 50.23% gain in the Nifty Pharma.
Gland Pharma to hold board meeting
On 14 February 2024
Gland Pharma Ltd spurts 2.01%, gains for third straight session
Gland Pharma Ltd is quoting at Rs 1928.95, up 2.01% on the day as on 12:49 IST on the NSE. The stock is up 22.6% in last one year as compared to a 19.03% gain in NIFTY and a 31.56% gain in the Nifty Pharma index.

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,69,497 Cr
₹ 1,540.00
(-3.99 %)
89.67
CIPLA₹ 1,12,773 Cr
₹ 1,396.80
(-1.84 %)
34.28
DRREDDY₹ 1,01,489 Cr
₹ 6,083.85
(-1.20 %)
25.50
DIVISLAB₹ 1,00,339 Cr
₹ 3,779.70
(1.09 %)
73.55
ZYDUSLIFE₹ 96,814 Cr
₹ 962.15
(-3.22 %)
35.99

Gland Pharma Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Gland Pharma Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Gland Pharma Ltd's share price is ₹1,749.65 as of April 12, 2024

Gland Pharma Ltd's P/E ratio is 42.59 times as of April 12, 2024.

Gland Pharma Ltd's most recent financial reports indicate a price-to-book ratio of 3.56, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Gland Pharma Ltd's market is 29,536 Cr as on April 12, 2024.

The current financial records of Gland Pharma Ltd show a 8.41% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Gland Pharma Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Gland Pharma Ltd's 52-week high and low as of April 12, 2024 are ₹1781.35 and ₹1735 respectively.

As of the Dec 2023 quarter, the promoter shareholding in Gland Pharma Ltd stands at 57.86%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 4.91% to 4.04%.